Description
Background:The use of anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy (ipilimumab) and anti-programmed cell-death 1 (anti-PD1) agents (nivolumab and pembrolizumab) in advanced melanoma have been associated with immune-related adverse events (...
| Date made available | 2021 |
|---|---|
| Publisher | SAGE Journals |
Research output
- 1 Article
-
Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database
Almutairi, A. R., Slack, M., Erstad, B. L., McBride, A. & Abraham, I., 2021, In: Therapeutic Advances in Drug Safety. 12Research output: Contribution to journal › Article › peer-review
Open Access5 Link opens in a new tab Scopus citations
Cite this
- DataSetCite